3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
714
Carcinoma, Renal Cell
227
Urinary Bladder Neoplasms
211
Carcinoma, Transitional Cell
109
Breast Neoplasms
99
Kidney Neoplasms
96
Neoplasms
88
Carcinoma, Non-Small-Cell Lung
80
Melanoma
79
Ovarian Neoplasms
75
Neoplasm Metastasis
69
Colorectal Neoplasms
64
Non-Muscle Invasive Bladder Neoplasms
56
Lung Neoplasms
56
Pancreatic Neoplasms
50
Sarcoma
44
Endometrial Neoplasms
42
Stomach Neoplasms
40
Uterine Cervical Neoplasms
36
Adenocarcinoma
34
Carcinoma, Hepatocellular
32
Wilms Tumor
31
Esophageal Neoplasms
30
Squamous Cell Carcinoma of Head and Neck
27
Triple Negative Breast Neoplasms
26
Head and Neck Neoplasms
25
Colonic Neoplasms
24
Testicular Neoplasms
23
Neuroblastoma
23
Urologic Neoplasms
22
Interventions
darolutamide
2
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Biochemically Recurrent Prostate Cancer
×
Genitourinary
×
90 days
×
Clear all
NCT05794906
2026-05-19
ARASTEP
Bayer
Phase 3
Active not recruiting
985 enrolled
NCT05526248
2026-03-11
ARAMON
Bayer
Phase 2
Completed
28 enrolled
14 charts